Antitumorigenic Effects of Tamoxifen, Raloxifene and the Combination on the Development of Breast Tumors Induced by Mouse Mammary Carcinoma Cells in Balb/c-J Female Mice

The antitumorigenic efficacy of tamoxifen, raloxifene, and their combination was evaluated on 4t1 estrogen-positive murine mammary carcinoma cells by determining their ability in breast tumor development in Balb/c-J female mice. Each mouse received intraperitoneally 0.1 ml of PBS solvent containing...

Full description

Saved in:
Bibliographic Details
Published in:Journal of chemotherapy (Florence) 2009-08, Vol.21 (4), p.426-433
Main Authors: Goel, A.J., Majumdar, S.K.
Format: Article
Language:English
Subjects:
Animals
Antibiotics. Antiinfectious agents. Antiparasitic agents
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Biological and medical sciences
drug combination
Female
Gynecology. Andrology. Obstetrics
Mammary gland diseases
Mammary Neoplasms, Experimental - drug therapy
Mammary Neoplasms, Experimental - pathology
Medical sciences
Mice
Mice, Inbred BALB C
Mouse breast cancer cells (4t1)
Pharmacology. Drug treatments
raloxifene
Raloxifene Hydrochloride - administration & dosage
Survival Rate
tamoxifen
Tamoxifen - administration & dosage
Tumor Cells, Cultured
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The antitumorigenic efficacy of tamoxifen, raloxifene, and their combination was evaluated on 4t1 estrogen-positive murine mammary carcinoma cells by determining their ability in breast tumor development in Balb/c-J female mice. Each mouse received intraperitoneally 0.1 ml of PBS solvent containing no drug, 12 mg (0.6 mg/kg) of tamoxifen, 36 mg (1.8 mg/kg) of raloxifene, or the combination of the two drugs (12 mg tamoxifen + 36 mg raloxifene) at 48-hour intervals for 35 days. Drug concentrations used were equivalent to human doses. Within the study period of 35 days, tamoxifen demonstrated the greatest effectiveness, as it allowed "progression-free survival," increased mouse life span by an average of 6 days, had the greatest number of survivors (90.9%), and those with the smallest spleen weight and volume. Raloxifene and combination groups, compared to the drug-untreated mice, did not significantly lengthen the life span or survivability, produced grossly enlarged spleens, and mice exhibited maladies such as leg paralysis and acute lethargy.
ISSN:1120-009X
1973-9478
DOI:10.1179/joc.2009.21.4.426